Glancy
Binkow & Goldberg LLP announces that all purchasers of the
securities of ARIAD
Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ:ARIA)
between December 12, 2011 and October 8, 2013, inclusive (the “Class
Period’) have until December 9, 2013, to file a motion to be appointed
as lead plaintiff in the shareholder lawsuit filed in the United States
District Court for the District of Massachusetts. The Complaint alleges
that the Company issued false and/or misleading statements and failed to
disclose material facts concerning ARIAD’s business, operations and
financial prospects.
A COPY OF THE COMPLAINT
IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE
CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER OR IF YOU PURCHASED ARIAD STOCK PRIOR TO THE
CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING
ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
ARIAD is an oncology company, engaged in the discovery, development and
commercialization of small-molecule drugs to treat cancer in patients
with aggressive cancers where current therapies are inadequate. ARIAD’s
first-approved cancer medicine, IclusigTM, is a tyrosine
kinase inhibitor (TKI) for the treatment of adult patients with certain
chronic or aggressive forms of leukemia who are resistant or intolerant
to prior TKI therapy.
On October 9, 2013, the Company announced that the U.S. Food and Drug
Administration placed a partial clinical hold on all new patient
enrollment in clinical trials of Iclusig following reports of
non-serious and serious adverse events in Iclusig-treated patients.
If you are a member of the Class described above you may move the Court
no later than December 9, 2013, to serve as lead plaintiff; however, you
must meet certain legal requirements. To learn
more about this action or if you purchased ARIAD shares prior to the
Class Period and have any questions concerning this Notice or your
rights or interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2013